Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms

Aurobindo Pharma Q1 net rises 25% to ₹1,032 cr; approves merger of three arms

Aurobindo Pharma riporta net profit +25.2% YoY (₹1,032 cr) e revenue +16.3% (₹9,150 cr) nel Q1 FY27, trainato da formulations U.S. +8.1% ed Europa +25.6%. Merger di tre subsidiary riduce overhead; trend di razionalizzazione rilevante per decisioni M&A e organizational efficiency.